Identification of a Specific Glycoprotein Ligand for P-selectin (CD62) on Myeloid Cells
Overview
Affiliations
P-selectin (CD62, GMP-140, PADGEM), a Ca(2+)-dependent lectin on activated platelets and endothelium, functions as a receptor for myeloid cells by interacting with sialylated, fucosylated lactosaminoglycans. P-selectin binds to a limited number of protease-sensitive sites on myeloid cells, but the protein(s) that carry the glycans recognized by P-selectin are unknown. Blotting of neutrophil or HL-60 cell membrane extracts with [125I]P-selectin and affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts were used to identify P-selectin ligands. A major ligand was identified with an approximately 250,000 M(r) under nonreducing conditions and approximately 120,000 under reducing conditions. Binding of P-selectin to the ligand was Ca2+ dependent and was blocked by mAbs to P-selectin. Brief sialidase digestion of the ligand increased its apparent molecular weight; however, prolonged digestion abolished binding of P-selectin. Peptide:N-glycosidase F treatment reduced the apparent molecular weight of the ligand by approximately 3,000 but did not affect P-selectin binding. Western blot and immunodepletion experiments indicated that the ligand was not lamp-1, lamp-2, or L-selectin, which carry sialyl Le(x), nor was it leukosialin, a heavily sialylated glycoprotein of similar molecular weight. The preferential interaction of the ligand with P-selectin suggests that it may play a role in adhesion of myeloid cells to activated platelets and endothelial cells.
Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma.
Pereira J, Arede L, Ferreira F, Matos A, Pereira D, Santos R Leukemia. 2024; 39(1):178-188.
PMID: 39455852 DOI: 10.1038/s41375-024-02446-w.
Novobrantseva T, Manfra D, Ritter J, Razlog M, ONuallain B, Zafari M Cancers (Basel). 2024; 16(16).
PMID: 39199551 PMC: 11352552. DOI: 10.3390/cancers16162778.
Macrophages and platelets in liver fibrosis and hepatocellular carcinoma.
Casari M, Siegl D, Deppermann C, Schuppan D Front Immunol. 2023; 14:1277808.
PMID: 38116017 PMC: 10728659. DOI: 10.3389/fimmu.2023.1277808.
Kulkarni A, Bazou D, Santos-Martinez M Int J Mol Sci. 2023; 24(21).
PMID: 37958838 PMC: 10647631. DOI: 10.3390/ijms242115855.
PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages.
Kauffman K, Manfra D, Nowakowska D, Zafari M, Nguyen P, Phennicie R Cancer Res Commun. 2023; 3(10):2182-2194.
PMID: 37819238 PMC: 10601817. DOI: 10.1158/2767-9764.CRC-22-0513.